Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.

@article{Haab2005LongtermOS,
  title={Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.},
  author={François Haab and Linda Cardozo and Christopher Key Chapple and A. J. M. De Ridder},
  journal={European urology},
  year={2005},
  volume={47 3},
  pages={376-84}
}
OBJECTIVE To examine safety and tolerability findings as primary endpoints, and efficacy outcomes as secondary endpoints, of solifenacin treatment over a period of up to 1 year. Long-term efficacy in the treatment of overactive bladder (OAB) syndrome depends in part on the patient's persistence with pharmacologic therapy. Agents with a favourable therapeutic index supporting high levels of patient satisfaction and persistence are needed. METHODS The present study was a 40-week open-label… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 52 extracted citations

Traitements visant la vessie hyperactive : Accent sur la pharmacothérapie.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC • 2016

Similar Papers

Loading similar papers…